Our Commitment to Combating

Janssen’s Ebola We have an important The preventive regimen, responsibility as Zabdeno® (Ad26.ZEBOV)and Mvabea® (MVA-BN-Filo), contains based a leading global on: healthcare company to do all we can to • Janssen’s AdVac® technology ® address this urgent (Zabdeno ) • ’s MVA-BN® unmet medical need. technology (Mvabea®)

Alex Gorsky, Chairman and CEO Available clinical data indicate that the Johnson & Johnson two-dose regimen induces a robust and durable immune response.1-7

225,000+ 15 people worldwide vaccinated Janssen with at least the first dose clinical studies OurOur ProgressProgress European Commission Phase 1, 2, 3 Approval & WHO trials show robust and Prequalification for durable antibody response Janssen’s preventive Ebola vaccine

PHASE 1 2-4,7 UK, US, Uganda,2-4,7 Kenya, Tanzania PHASE 1 PHASE 2 5,13-15 UK, US, Uganda, Kenya, Tanzania 2 US, UK, France, Uganda, Côte d’Ivoire, 1 Kenya, Burkina Faso, Tanzania, Mozambique, 23 Nigeria,Mozambique, Guinea Nigeria,*, Liberia Guinea*, Sierra*, LiberiaLeone**,, Mali* 1 2 3 Sierra Leone*, Mali*, Uganda*, DRC*

1 2 3 4 CAMPAIGN 16 RwandaVACCINATION CAMPAIGN 16 Rwanda Studies PHASE 3 8,17 Spanning DRCPHASE*, Sierra 3 8,17 Leone, US DRC*, Sierra Leone, US, Rwanda*, 3 Continents Burkina Faso, France, Kenya, *indicates studies for which Janssen were collaborators. Tanzania, Uganda, United Kingdom Ebola Timeline The Ebola virus was first discovered in 1976 near the in what is now the Democratic Republic of the Congo (DRC).18 Over the past 45 years, there have been multiple Ebola outbreaks.19 The worst to date was the West African Ebola epidemic, which caused nearly 30,000 cases and more than 11,000 deaths across Guinea, Libera and Sierra Leone in 2014-2016.20 The world’s second-largest Ebola outbreak took place in the DRC in 2018-2020, causing more than 3,000 cases and 2,000 deaths.21 In 2021, new outbreaks were reported in the DRC and Guinea.32

Janssen begins vaccine research with NIH 2002 support against filoviruses, which include Ebolavirus22 Working in Partnership Emergency of International Johnson & Johnson has made a significant investment Concern was declared by WHO for the Ebola in our Ebola vaccine development program. We are also outbreak in West Africa23 grateful for development and funding support from: J&J commits to accelerate development 2014 • Bavarian Nordic A/S and expand production of an Ebola vaccine regimen together with Bavarian NordicA/ S24 Biomedical Advanced Research and Development • First-in-human study began in UK2 Authority (BARDA) • Innovative Medicines Initiative (IMI) Announcement of IMI-supported consortia, 25 including financial support from the • National Institutes of Health (NIH) Biomedical Advanced Research and 2015 Development Authority (BARDA)26 Additionally, we acknowledge the support of our many ‘EBOVAC-Salone’ study begins in clinical program partners: Sierra Leone27 • Centre Muraz • Ministry of Health First clinical data for Ebola vaccine • Coalition for Epidemic and Sanitation Sierra regimen published in JAMA2 Preparedness Leone Janssen completes submission to WHO 2016 for Emergency Use Assessment and Innovations • Republic of Rwanda Listing (EUAL)28 • College of Medicine Ministry of Health and Allied Health • Uganda Virus Research First long-term clinical data for Ebola 1 Sciences (University of Institute vaccine regimen published in JAMA 2017 New partnership with BARDA to support Sierra Leone) • University of Antwerp U.S. licensure of vaccine regimen29 • Democratic Republic • University of Oxford of the Congo Ministry • Université de Kinshasa of Public Health Second-largest Ebola outbreak • Vibalogics GmbH begins in North Kivu, DRC21 2018 • Grameen Foundation • Walter Reed Army Inserm • Institute of Research Public Health Emergency of International • Inserm Transfert • World Health Concern was declared by WHO30 • London School of Organization WHO SAGE committee recommends evaluation Hygiene & Tropical of Janssen vaccine regimen in the DRC31 • World Vision Ireland Medicine Janssen announces it will provide up to • 700,000 vaccine regimens for DRC and Rwanda 2019 vaccination initiatives16,17 Janssen files for accelerated EU approval of ...and all the people who participated in clinical trials vaccine regimen32 during the Ebola epidemic. Conditional approval from the Rwandan Health Authority for use in exceptional emergency Commitment to circumstances16

Pandemic Preparedness Second-largest Ebola outbreak in North Johnson & Johnson is one of the few innovative Kivu, DRC ends healthcare companies that is actively engaged on The European Commission approves 2020 pandemic preparedness and response. Through Janssen’s Ebola vaccine regimen our Janssen Pharmaceutical Companies, we are developing new vaccines and/or treatments to combat WHO prequalifies Janssen’s Ebola infectious diseases, including:33,34 vaccine regimen

• COVID-19 • Influenza J&J announces it will provide up to 200,000 • Ebola • Tuberculosis vaccine regimens to a WHO early access 2021 clinical program in West Africa • Hepatitis B • Zika To date, more than 225,000 people worldwide • HIV have been vaccinated with at least the first dose of Janssen’s Ebola vaccine regimen

Program Support and Funding Janssen’s investigational Ebola vaccine regimen was developed in a collaborative research program with the NIH and received direct funding and preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, under Contract Numbers HHSN272200800056C and HHSN272201200003I, respectively. Further funding for the Ebola vaccine regimen has been provided in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, BARDA, under Contract Numbers HHSO100201700013C and HHSO100201500008C. The Innovative Medicines Initiative (IMI), which is supported by the European Commission, provided funding through the IMI Ebola+ Program to support a number of consortia that are conducting multiple clinical trials and other vaccine development activities. The consortia funded by the Innovative Medicines Initiative 2 (IMI2) Joint Undertaking are EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). This Joint Undertaking receives support from the EU’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

References 1. Winslow RL, Milligan ID, Voysey M, et al. Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara– who.int/emergencies/diseases/ebola/drc-2019. Last accessed June 2020. 22. US Securities and Exchange Commission. Annual Vectored Ebola Vaccines at 1 Year. JAMA. 2017;317(10):1075. 2. Milligan ID, Gibani MM, Sewell R, et al. Safety and Immunogenicity of report pursuant to section 13 or 15(d) of the securities exchange act of 1934. Available at: https://www.sec.gov/Archives/edgar/data/ Novel Adenovirus Type 26– and –Vectored Ebola Vaccines. JAMA. 2016;315(15):1610. 3. Anywaine Z, 1126136/000110465909025432/a09-9494. Last accessed June 2020. 23. World Health Organisation (WHO). Ebola outbreak in West Whitworth H, Kaleebu P, et al. Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and Africa declared a public health emergency of international concern. Available at: http://www.euro.who.int/en/health-topics/ MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized in Uganda and Tanzania. J Infect Dis. 2019; communicable-diseases/pages/news/news/2014/08/ebola-outbreak-in-west-africa-declared-a-publichealth-emergency-of- 220(1):46-56. 4. Mutua G, Anzala O, Luhn K, et al. Safety and Immunogenicity of a 2-Dose Regimen With international-concern. Last accessed June 2020. 24. Johnson & Johnson. Johnson & Johnson Responds to Ebola Crisis with Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya. J Infect Commitment to Accelerate Vaccine Program in Collaboration with the US National Institutes of Health (NIH) and Provide Dis. 2019;220(1):57-67. 5. Thiebaut R, Snape MD, Goldtsein N. Safety and immunogenicity of 2-dose Ebola vaccine regimen with Humanitarian Relief Aid. Available at: https://www.jnj.com/media-center/press-releases/johnson-johnson-responds-toebola-crisis- Ad26.ZEBOV and MVA-BN-Filo in a phase II clinical trial in Europe. (EBOVAC2) - ECCMID Live. April 2019. 6. Leigh B, Ishola D, with-commitment-to-accelerate-vaccineprogram- in-collaboration-with-the-us-national-institutes-of-health-nih-and- Manno D, et al. Safety and immunogenicity of a 2-dose Ebola vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo in a Phase III providehumanitarian-relief-aid. Last accessed June 2020. 25. Johnson & Johnson. Johnson & Johnson Announces Formation of clinical trial in Sierra Leone - ECCMID Live. April 2019. 7. Goldstein N, Bockstal V, Robinson C, et al. Anamnestic response after Ebola Vaccine Development Consortia, Gains Funding from Innovative Medicines Initiative. Available at: https://www.jnj.com/ antigen re-exposure following Ebola vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo in a phase I study - ECCMID Live. April media-center/press-releases/johnson-johnsonannounces-formation-of-ebola-vaccine-development-consortiagains-funding-from- 2019. 8. Janssen Data on File. Overview of Clinical Studies Evaluating the Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen. June 2020. innovative-medicines-initiative. Last accessed June 2020. 26. Johnson & Johnson. Johnson & Johnson Announces BARDA Funding 9. ClinicalTrials.gov. A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants. Available at: https:// Award to Accelerate Ebola Vaccine Program. Available at: https://www.jnj.com/media-center/press-releases/johnson-johnson- clinicaltrials.gov/ct2/show NCT03929757?term=EBL2005&draw=2&rank=1. Last accessed June 2020. 10. ClinicalTrials.gov. A Study announces-barda-funding-award-to-accelerate-ebola-vaccine-program. Last accessed June 2020. 27. Johnson & Johnson. Johnson of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants. Available at: https:// & Johnson Announces Start of Clinical Trial of Ebola Vaccine Regimen in Sierra Leone. Available at: https://www.jnj.com/ clinicaltrials.gov/ct2/show/NCT04228783?term=EBL3004&draw=2&rank=1. Last accessed June 2020. 11.ClinicalTrials.gov. media-center/press-releases/johnson-johnson-announcesstart-of-clinical-trial-of-ebola-vaccine-regimen-in-sierra-leone. Last Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo. Available accessed June 2020. 28. Johnson & Johnson. Johnson & Johnson Announces World Health Organization will Review Ebola Vaccine at: https://clinicaltrials.gov/ct2/show/NCT02661464. Last accessed June 2020. 12. Janssen Data on File. Ebola vaccine regimen: Regimen for Emergency Use Assessment and Listing (EUAL). Available at: https://www.jnj.com/media-center/press-releases/ vaccination figures June 2020. 13. ClinicalTrials.Gov. Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for johnson-johnson-announces-world-healthorganization-will-review-ebola-vaccine-regimen-for-emergency-useassessment-and- Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults. listing-eual. Last accessed June 2020. 29. Johnson & Johnson. Johnson & Johnson Advances Investigational Ebola Prime-boost Available at: https://clinicaltrials.gov/ct2/show/NCT02564523?term=NCT02564523&draw=2&rank=1. Last accessed June 2020. 14. Vaccine Regimen with New Partnership. Available at: https://www.jnj.com/media-center/press-releases/johnson-johnson-advances- ClinicalTrials.Gov. Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26. investigationalebola-prime-boost-vaccine-regimen-with-new-partnership. Last accessedJune 2020. 30. World Health Organisation ZEBOV/MVA-BN-Filo. Available at: https://clinicaltrials.gov/ct2/show/NCT02598388?term=NCT02598388&draw=2&rank=1. Last (WHO). Ebola outbreak in the Democratic Republic of the Congo declared a Public Health Emergency of International Concern. accessed June 2020. 15. ClinicalTrials.Gov. Partnership for Research on Ebola (PREVAC) (NCT02876328). Available at: Available at: https://www.who.int/news-room/detail/17-07-2019-ebola-outbreak-in-the-democratic-republic-of-the-congo-declared- https://clinicaltrials.gov/ct2/ show/NCT02876328?term=NCT02876328&draw=2&rank=1. Last accessed June 2020. 16. Johnson & a-public-health-emergency-of-international-concern. Last accessed June 2020. 31. Strategic Advisory Group of Experts (SAGE) on Johnson. Johnson & Johnson Announces Commitment to Support Republic of Rwanda’s Preparedness Against Ebola Outbreak. . Interim Recommendations on Vaccination against Ebola Virus Disease (EVD). Available at: https://www.who.int/ Available at: https://www.jnj.com/johnson-johnson-announces-commitment-to-support-republic-of-rwandas-preparedness-against- immunization/policy/ position_papers/interim_ebola_recommendations_may_2019.pdf?ua=1. Last accessed June 2020. 32. ebola-outbreak. Last accessed June 2020. 17. Johnson & Johnson. Johnson & Johnson Announces Donation of up to 500,000 Johnson & Johnson. Johnson & Johnson Announces Submission of EuropeanMarketing Authorisation Applications for Janssen’s Regimens of Janssen’s Investigational Ebola Vaccine to Support Outbreak Response in Democratic Republic of the Congo (DRC). Investigational Ebola Vaccine Regimen. Available at: https://www.jnj.com/johnson-johnsonannounces-submission-ofeuropean- Available at: https://www.jnj.com/johnson-johnsonannounces-donation-of-upto-500-000-regimens-of-janssens-investigational- marketing-authorisation-applications-for-janssens-investigational-ebola-vaccine-regimen. Last accessed June 2020. 33. Janssen. ebola-vaccine-to-support-outbreak-response-in-democratic-republicof-the-congo-drc. Last accessed June 2020. 18. CDC. History Discovery: Towards a world free of infectious diseases Available at: https://www.janssen.com/infectious-diseases-and-vaccines/ of Ebola Virus Disease. Available at: https://www.cdc.gov/vhf/ebola/history/summaries.html. Last accessed June 2020. 19. CDC. discovery. Last accessed June 2020. 34. Johnson & Johnson. Our Efforts to Develop a Vaccine and Identify Therapies for COVID-19. Years of Ebola Virus Disease Outbreaks. Available at: https://www.cdc.gov/vhf/ebola/history/chronology.html?CDC_AA_ Available at: https://www.jnj.com/coronavirus/prevention-and-treatment. Last accessed June 2020. 32 WHO AFRO (2021). WHO refVal=https%3A%2F%2Fwww.cdc.gov%2Fvhf%2Febola%2Foutbreaks%2Fhistory%2Fchronology.html. Last accessed June 2020. steps up efforts to curb Ebola outbreaks in Guinea and the Democratic Republic of the Congo. Available at: https://www.afro.who. 20. The Centers for Disease Control and Prevention. 2014-2016 Ebola Outbreak in West Africa. March 8, 2019. Available at: https:// int/news/who-steps-efforts-curb-ebola-outbreaks-guinea-and-democratic-republic-congo. © Johnson & Johnson www.cdc.gov/vhf/. Last accessed: June 2020. 21. World Health Organisation. 2020. Ebola Health Update. Available at: https://www. Last accessed March 2021 Last updated: May 2021